Lijie Xing
Overview
Explore the profile of Lijie Xing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhong Y, Liu Y, Xing L, Zhao M, Wu W, Wang Q, et al.
Foods
. 2022 Feb;
11(4).
PMID: 35206014
This study aimed to evaluate the efficiency of microencapsulated apple polyphenols (MAP) in controlling cathepsin activity and texture, as well as inhibiting protein oxidation and metmyoglobin formation in lamb meat...
12.
Xing L, He Q, Xie L, Wang H, Li Z
Haematologica
. 2021 Dec;
107(5):1226-1228.
PMID: 34937321
No abstract available.
13.
Cho S, Xing L, Anderson K, Tai Y
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885245
The incorporation of novel agents in recent treatments in multiple myeloma (MM) has improved the clinical outcome of patients. Specifically, the approval of monoclonal antibody (MoAb) against CD38 (daratumumab) and...
14.
Xing L, Wang S, Liu J, Yu T, Chen H, Wen K, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5376-5388.
PMID: 34301753
Purpose: Efforts are required to improve the potency and durability of CD38- and BCMA-based immunotherapies in human multiple myeloma. We here delineated the molecular and cellular mechanisms underlying novel immunomodulatory...
15.
Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur M, et al.
Sci Adv
. 2021 Jun;
7(23).
PMID: 34088671
Immunomodulatory drugs (IMiDs) have markedly improved patient outcome in multiple myeloma (MM); however, resistance to IMiDs commonly underlies relapse of disease. Here, we identify that tumor necrosis factor (TNF) receptor-associated...
16.
Yu T, Chaganty B, Lin L, Xing L, Ramakrishnan B, Wen K, et al.
Blood Cancer J
. 2020 Nov;
10(11):110.
PMID: 33149123
Therapeutically targeting CD138, a define multiple myeloma (MM) antigen, is not yet approved for patients. We here developed and determined the preclinical efficacy of VIS832, a novel therapeutic monoclonal antibody...
17.
Cho S, Lin L, Xing L, Li Y, Wen K, Yu T, et al.
Blood Adv
. 2020 Sep;
4(17):4195-4207.
PMID: 32898244
We investigated here the novel immunomodulation and anti-multiple myeloma (MM) function of T cells engaged by the bispecific T-cell engager molecule AMG 701, and further examined the impact of AMG...
18.
Lin L, Cho S, Xing L, Wen K, Li Y, Yu T, et al.
Leukemia
. 2020 Jul;
35(3):752-763.
PMID: 32632095
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a...
19.
Cho S, Lin L, Xing L, Li Y, Yu T, Anderson K, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32516895
The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy. Novel immunotherapies will significantly improve patient outcome via simultaneously targeting malignant plasma cell (PC) and reversing...
20.
Xing L, Lin L, Yu T, Li Y, Cho S, Liu J, et al.
Leukemia
. 2020 Feb;
34(8):2150-2162.
PMID: 32060401
To target mechanisms critical for multiple myeloma (MM) plasma cell adaptations to genomic instabilities and further sustain MM cell killing, we here specifically trigger DNA damage response (DDR) in MM...